- Home
- ZCAR vs KPRX Comparison
ZCAR vs KPRX Comparison
Compare ZCAR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCAR
- KPRX
- Stock Information
- Founded
- ZCAR 2013
- KPRX 1998
- Country
- ZCAR India
- KPRX United States
- Employees
- ZCAR N/A
- KPRX N/A
- Industry
- ZCAR Blank Checks
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ZCAR Finance
- KPRX Health Care
- Exchange
- ZCAR Nasdaq
- KPRX Nasdaq
- Market Cap
- ZCAR 11.6M
- KPRX 12.0M
- IPO Year
- ZCAR N/A
- KPRX N/A
- Fundamental
- Price
- ZCAR $0.52
- KPRX $3.47
- Analyst Decision
- ZCAR
- KPRX Strong Buy
- Analyst Count
- ZCAR 0
- KPRX 1
- Target Price
- ZCAR N/A
- KPRX $10.00
- AVG Volume (30 Days)
- ZCAR 1.7M
- KPRX 46.3K
- Earning Date
- ZCAR 02-14-2025
- KPRX 03-24-2025
- Dividend Yield
- ZCAR N/A
- KPRX N/A
- EPS Growth
- ZCAR N/A
- KPRX N/A
- EPS
- ZCAR N/A
- KPRX 1.69
- Revenue
- ZCAR $9,117,419.00
- KPRX $16,020,000.00
- Revenue This Year
- ZCAR N/A
- KPRX N/A
- Revenue Next Year
- ZCAR N/A
- KPRX N/A
- P/E Ratio
- ZCAR N/A
- KPRX $2.05
- Revenue Growth
- ZCAR N/A
- KPRX N/A
- 52 Week Low
- ZCAR $0.50
- KPRX $3.00
- 52 Week High
- ZCAR $183.00
- KPRX $6.75
- Technical
- Relative Strength Index (RSI)
- ZCAR 29.79
- KPRX 44.69
- Support Level
- ZCAR $1.12
- KPRX $3.40
- Resistance Level
- ZCAR $1.74
- KPRX $3.75
- Average True Range (ATR)
- ZCAR 0.19
- KPRX 0.22
- MACD
- ZCAR -0.00
- KPRX -0.03
- Stochastic Oscillator
- ZCAR 1.93
- KPRX 37.65
About ZCAR Zoomcar Holdings Inc.
Zoomcar Holdings Inc is India's largest marketplace for cars on rent. Zoomcar is a leading emerging-market-focused peer-to-peer car-sharing marketplace, with approximately 21,000 vehicles registered through its platform. The Company derives its revenue principally from short-term self-drive rentals and vehicle subscriptions. The self-drive rental business generates the majority of revenue. Geographically The company operates in India, Egypt, Indonesia, Vietnam, and the Philippines, Out of which the majority of revenue is derived from India.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.